Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABCL 
Abcellera Biologics Inc (ABCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ABCL (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.33
1 Year Target Price $9.33
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.23% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.34B USD | Price to earnings Ratio - | 1Y Target Price 9.33 |
Price to earnings Ratio - | 1Y Target Price 9.33 | ||
Volume (30-day avg) 9 | Beta 0.65 | 52 Weeks Range 1.89 - 5.82 | Updated Date 09/13/2025 |
52 Weeks Range 1.89 - 5.82 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -290.24% |
Management Effectiveness
Return on Assets (TTM) -10.96% | Return on Equity (TTM) -15.64% |
Valuation
Trailing PE - | Forward PE 27.47 | Enterprise Value 924785121 | Price to Sales(TTM) 40.63 |
Enterprise Value 924785121 | Price to Sales(TTM) 40.63 | ||
Enterprise Value to Revenue 28.13 | Enterprise Value to EBITDA 5.3 | Shares Outstanding 298832992 | Shares Floating 202749166 |
Shares Outstanding 298832992 | Shares Floating 202749166 | ||
Percent Insiders 22.94 | Percent Institutions 38.47 |
Upturn AI SWOT
Abcellera Biologics Inc
Company Overview
History and Background
Abcellera Biologics Inc. was founded in 2012 in Vancouver, Canada. It is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed into drugs to prevent and treat disease.
Core Business Areas
- Antibody Discovery Platform: Abcellera's core business is its antibody discovery platform, which integrates microfluidics, high-throughput imaging, genomics, computation, and protein engineering to search and analyze single B cells to identify therapeutically relevant antibodies.
- Drug Development Partnerships: Abcellera partners with pharmaceutical and biotechnology companies to discover and develop new antibody-based therapies. They receive research fees, milestone payments, and royalties on sales of approved drugs.
Leadership and Structure
The CEO is Carl Hansen. The organizational structure is based on functional teams specializing in various aspects of antibody discovery and development.
Top Products and Market Share
Key Offerings
- Antibody Discovery Services: Abcellera offers end-to-end antibody discovery services to its partners. Market share data is difficult to obtain, but their primary competitors are other CROs and in-house discovery teams at large pharma companies. Competitors include companies like Charles River Laboratories and WuXi Biologics.
- Therapeutic Programs: While not a 'product' in the traditional sense, Abcellera has a portfolio of therapeutic programs in development in partnership with other companies, generating revenue through milestones and royalties. The main competitor here is the biotech and pharma industry as a whole.
Market Dynamics
Industry Overview
The antibody therapeutics market is a large and growing market driven by advances in biotechnology and the increasing prevalence of chronic diseases and cancer.
Positioning
Abcellera positions itself as a technology leader in antibody discovery, offering a faster, more efficient, and more comprehensive approach than traditional methods. Their competitive advantage lies in their integrated platform and data-driven approach.
Total Addressable Market (TAM)
The TAM for antibody therapeutics is projected to be hundreds of billions of dollars annually. Abcellera is positioned to capture a significant share through its discovery platform and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Strong partnerships with leading pharmaceutical companies
- Data-driven approach to antibody discovery
- Experienced management team
- Strong cash position
Weaknesses
- Reliance on partnerships for revenue
- Long drug development timelines
- High R&D costs
- Limited control over drug development process
- Relatively new company
Opportunities
- Expansion of partnerships with pharmaceutical companies
- Development of proprietary antibody therapeutics
- Application of platform to new disease areas
- Increased adoption of AI and machine learning in drug discovery
- Strategic acquisitions
Threats
- Competition from other antibody discovery companies
- Failure of partnered drug programs
- Changes in regulatory environment
- Economic downturn
- Patent disputes
Competitors and Market Share
Key Competitors
- Charles River Laboratories (CRL)
- WuXi Biologics (2269.HK)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Abcellerau2019s advantage is its technology platform. Disadvantages are reliance on partnerships and long development timelines.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the success of partnered programs, particularly bamlanivimab. However, revenue can be volatile.
Future Projections: Future growth is dependent on the success of future partnered programs and expansion of the platform. Analyst estimates vary. However, analysts generally expect an increase in revenue over the coming years. This data is subject to change.
Recent Initiatives: Recent initiatives include expanding the platform capabilities and securing new partnerships.
Summary
Abcellera Biologics is a novel company with a potentially disruptive antibody discovery platform. Its strength lies in its technology, while its weakness is reliance on partnerships. The company needs to carefully manage its R&D spending and mitigate the risk of partnered program failures. Growth prospects depend on platform expansion and partnership success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abcellera Biologics Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-12-11 | CEO, President & Chairperson Dr. Carl L.G. Hansen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 596 | Website https://www.abcellera.com |
Full time employees 596 | Website https://www.abcellera.com | ||
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.